Rituximab for the first-line treatment of stage III-IV follicular lymphoma

  • Technology appraisal guidance
  • TA243
  • Published: 
Download guidance (PDF)

Update information

February 2014: Implementation section updated to clarify that rituximab is recommended as an option for treating stage III to IV follicular lymphoma.

ISBN: 978-1-4731-6702-5